40,697 Shares in Yarrow Bioscience $YARW Purchased by Two Sigma Securities LLC

Key Points

• Two Sigma Securities purchased 40,697 shares of Yarrow Bioscience, valued at approximately $26,000, giving it a 6.07% stake. Institutional investors collectively own 83.78% of the company.
• Yarrow Bioscience reported a significant quarterly loss, with earnings of -$3.51 per share versus the consensus estimate of -$0.18, while revenue of $0.10 million fell short of the $0.20 million forecast.
• The stock opened at $30.21, compared with a 12-month range of $14.02 to $46.95. Analysts have a consensus “Hold” rating and a $58 price target, while the company recently paid a special $19-per-share dividend.

Two Sigma Securities LLC purchased a new position in shares of Yarrow Bioscience (NASDAQ:YARW - Free Report) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 40,697 shares of the company's stock, valued at approximately $26,000. Two Sigma Securities LLC owned about 6.07% of Yarrow Bioscience as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently bought and sold shares of YARW. Nantahala Capital Management LLC acquired a new stake in shares of Yarrow Bioscience in the second quarter valued at approximately $1,301,400,000. ADAR1 Capital Management LLC acquired a new position in shares of Yarrow Bioscience during the 2nd quarter worth approximately $1,920,000. BlackRock Inc. bought a new stake in Yarrow Bioscience in the 2nd quarter valued at $29,000. GSA Capital Partners LLP bought a new stake in Yarrow Bioscience in the 2nd quarter valued at $47,000. Finally, Rangeley Capital LLC lifted its holdings in Yarrow Bioscience by 18.1% during the 1st quarter. Rangeley Capital LLC now owns 118,064 shares of the company's stock valued at $71,000 after purchasing an additional 18,064 shares during the last quarter. Institutional investors own 83.78% of the company's stock.

Yarrow Bioscience Stock Performance

Shares of NASDAQ:YARW opened at $30.21 on Monday. Yarrow Bioscience has a 12-month low of $14.02 and a 12-month high of $46.95. The company has a market cap of $80.66 million, a price-to-earnings ratio of -2.06 and a beta of 2.01.

Yarrow Bioscience (NASDAQ:YARW - Get Free Report) last released its quarterly earnings results on Thursday, August 13th. The company reported ($3.51) earnings per share for the quarter, missing analysts' consensus estimates of ($0.18) by ($3.33). The business had revenue of $0.10 million during the quarter, compared to analyst estimates of $0.20 million. Yarrow Bioscience had a negative net margin of 4,726.21% and a negative return on equity of 84.40%.

Yarrow Bioscience Announces Dividend

The business also recently announced a special dividend, which was paid on Thursday, July 23rd. Stockholders of record on Wednesday, July 22nd were given a dividend of $19.00 per share.

Wall Street Analysts Forecast Growth

A number of research firms have commented on YARW. BTIG Research began coverage on shares of Yarrow Bioscience in a research report on Monday, August 3rd. They set a "buy" rating and a $58.00 price objective for the company. Wall Street Zen raised shares of Yarrow Bioscience to a "hold" rating in a research report on Saturday, August 22nd. Finally, TD Cowen started coverage on shares of Yarrow Bioscience in a research note on Tuesday, July 28th. They set a "buy" rating for the company. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of "Hold" and a consensus target price of $58.00.

Yarrow Bioscience Company Profile

VYNE Therapeutics Inc, a pharmaceutical company, focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions. The company develops FCD105, a topical combination foam that has completed Phase III clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, which is in Phase IIa preclinical trial for the treatment of mild-to-moderate atopic dermatitis. It is also developing VYN201, a bromodomain and extra-terminal (BET) inhibitor for various immuno-inflammatory diseases, including skin diseases; and VYN202, BET inhibitor compounds that are selective for bromodomain 2.

Want to see what other hedge funds are holding YARW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Yarrow Bioscience (NASDAQ:YARW - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source